Debu Tripathy, MD,

Articles

Dr. Tripathy on the Importance of Biosimilars in Oncology

July 26th 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of biosimilars in oncology.

Dr. Tripathy on the Management of HR+ Early-Stage Breast Cancer

July 13th 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the management of hormone-receptor (HR)-positive early-stage breast cancer.

Dr. Tripathy on Impact of Olaparib Approval in BRCA-Positive Breast Cancer

March 8th 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the FDA approval of olaparib (Lynparza) for patients with BRCA-positive breast cancers and the impact it has had on clinical practice. Tripathy shared this insight in an interview during the 35th Annual Miami Breast Cancer Conference.

Dr. Tripathy Discusses Lurbinectedin in Breast Cancer

December 14th 2017

Debu Tripathy, MD, professor of medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses lurbinectedin (PM01183) for patients with breast cancer.

Dr. Tripathy Discusses Neratinib in HER2+ Breast Cancer

December 12th 2017

Debu Tripathy, MD, professor of medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neratinib (Nerlynx) for the treatment of patients with HER2-positive breast cancer.

Dr. Tripathy Discusses Immunotherapy in HER2+ Breast Cancer

June 19th 2017

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses immunotherapy in HER2-positive breast cancer.

Dr. Tripathy on Standard and Emerging Treatment Advances for HER2+ Breast Cancer

March 22nd 2017

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses standard and emerging advances in the treatment of patients with HER2-positive breast cancer.

Dr. Tripathy on Neoadjuvant Treatment Strategies in HER2+ Breast Cancer

March 10th 2017

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neoadjuvant treatment strategies in HER2-positive breast cancer.

Dr. Tripathy on Immunotherapy Potential in HER2-Positive Breast Cancer

November 19th 2016

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the potential role of immunotherapy in the treatment of patients with HER2-positive breast cancer.

Dr. Tripathy on Neoadjuvant Agents for HER2+ Breast Cancer

November 16th 2016

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses agents that are available and in development in the neoadjuvant setting as treatments for patients with HER2-positive breast cancer.

Dr. Tripathy on Ixabepilone in Patients With TNBC

March 13th 2016

Debu Tripathy, MD, chair, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the use of ixabepilone as a treatment for patients with triple-negative breast cancer (TNBC).

Dr. Debu Tripathy on Molecular Predictors of Outcome in Breast Cancer

January 28th 2016

Debu Tripathy, MD, professor of Medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses molecular predictors of outcome for patients with ER-positive breast cancer.

Dr. Tripathy on the Possibility of Curing Metastatic Breast Cancer

February 26th 2015

Debu Tripathy, MD, professor of medicine, chair, department of breast medical oncology, The University of Texas MD Anderson Cancer Center, discusses the possibility of one day being able to cure metastatic breast cancer.

Dr. Tripathy Provides an Overview of the SystHERs Registry

September 2nd 2014

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, provides an overview of the SystHERs registry.

Dr. Tripathy on Decision-Making for Sequencing Therapies for HER2-Positive MBC

July 18th 2014

Debu Tripathy, MD, discusses a decision-making framework for sequencing therapies for HER2-positive metastatic breast cancer.

Dr. Tripathy on the Treatment of Patients With MBC

April 29th 2014

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses advances in the treatment of metastatic breast cancer.

Dr. Tripathy on Personalized Therapies in Advanced BC

March 20th 2014

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses new personalized therapies on the horizon for advanced breast cancer.

Dr. Tripathy on Adjuvant Bisphosphonates in BC

March 7th 2014

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses using adjuvant bisphosphonates as a treatment option for patients with breast cancer.

Dr. Tripathy on Markers of Resistance in Breast Cancer

February 26th 2014

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses markers of resistance in patients with HER2+ breast cancer.

Dr. Debu Tripathy on Integrative Oncology

October 15th 2013

Debu Tripathy, MD, co-leader, Women's Cancer Program, Norris Comprehensive Cancer Center, University of Southern California, discusses integrative oncology

NEXT PAGE
PREVIOUS PAGE